Studies to Enhance FDA Communications Addressing Biosimilar Drug Products: Patient Focus Groups 2020

Data to Support Drug Product Communications

Biosimilar Basics Infographic

Studies to Enhance FDA Communications Addressing Biosimilar Drug Products: Patient Focus Groups 2020

OMB: 0910-0695

Document [pdf]
Download: pdf | pdf
Biosimilar Basics
Biosimilars are safe and effective
biologic medications for treating
many illnesses such as chronic
skin and bowel diseases, arthritis,
kidney conditions and cancer.

Biologic medications are generally made from
natural sources and developed using advanced science.
Biosimilars are FDA-approved medications that
are compared to another medication
— the original biologic.

Biosimilar &
Original Biologic
.

Same benefits

.

Same potential
side effects

.

Same strength
and dosage

.

Given the same way

Biosimilars are made with the same
types of natural sources as the original
biologic they were compared to —
and provide the same treatment benefits.

More options

Biosimilars may provide
patients with more access
to important treatments.

More competition in the
health care market
Lower costs

Biosimilars
are approved
by FDA after a
careful review of
data, studies, and tests.

FDA monitors the safety and
effectiveness of all medications
after their approval.
Check for medication quality
during production

Review patient safety reports

Visit www.FDA.gov/biosimilars
and talk with your doctor to learn more.


File Typeapplication/pdf
File TitleBiosimilar Basics
SubjectFDA, Biosimilars, FDA-approved, treatment, medications, infographic
AuthorUnited States Food and Drug Administration
File Modified2019-09-19
File Created2019-09-17

© 2024 OMB.report | Privacy Policy